A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Substitution, Crossover, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pf 06650833 Delivered in Multiple Formulations in Healthy Subjects Under Fasted and Fed Conditions

Trial Profile

A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Substitution, Crossover, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pf 06650833 Delivered in Multiple Formulations in Healthy Subjects Under Fasted and Fed Conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs PF 6650833 (Primary) ; PF 6650833 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Nov 2017 Results from the single and multiple ascending dose (SAD, MAD) studies of PF-06650833 in healthy subjects assessing safety and efficacy, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top